Some healthcare stocks are undergoing significant successes that has evoked interest of the investors. Eager to capture the development, these are quickly being lapped up.
Cogstate Limited (ASX: CGS)
has demonstrated strong financial results as well as excellent operational performance. Revenue grew by 22 per cent to $53.1 million, continuing with an upward trend and underpinned by robust results in clinical trial revenues. It has recorded NPAT of $10.1 million, up by 86 per cent. Eisai license amendment creates a favourable outlook for the company, enabling broader use of technology as a trial pre-screening tool. Moreover, it has also declared a dividend of $0.02 per ordinary share (fully franked) post year-end.
Mesoblast Limited (ASX: MSB)
is a leading company in providing cellular medicines for inflammatory diseases. It has recently launched its RyoncilTM, the only MSC product approved by the US FDA. This launch was highlighted by Global Healthcare Conferences, which may further boost its sales. Due to this, revenue from cell therapy grew by 1.91 times to USD 17.2 million in comparison to the prior year. The gross sales of RyoncilTM were USD 13.2 million. Moreover, the company is making progress in its product line, with one product getting accelerated FDA approval, especially to cure patients suffering from HFEF. The addressable target market for this product is more than 10 billion.
PYC Therapeutics Limited (ASX: PYC)
is a precision medicine company. It is progressing towards its drug (PYC-003), which addresses Polycystic Kidney Disease. The company has completed Part A of the combined Phase 1a and 1b clinical trial. Moreover, the company’s other product, PYC-001, has shown encouraging results in the Phase 1a SAD study, and it is moving towards Phase 1b MAD in 2025 to evaluate safe and efficacy profile. If the momentum continues, the product will soon benefit the company.
Race Oncology Limited (ASX: RAC)
is on a mission to be at the heart of cancer care. It has successfully opened a trial site at Queen Mary Hospital in Hong Kong for its Phase One clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. Moreover, it has received permission from the Hong Kong Department of Health for further trials in the Prince of Wales Hospital in the coming weeks. These trials are in Hong Kong because of faster trial recruitments, highly experienced clinicians, etc. Overall, the success of this trial will be a key step for the company.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
